Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Surface markers of lymphocyte activation and markers of cell proliferation

Shipkova, Maria, Wieland, Eberhard · 2012 · Clinica Chimica Acta

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cca.2011.11.006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 82

  1. Waki, 2006, UNOS Liver Registry: ten year survivals, Clin Transpl, 29
  2. Kaneku, 2006, Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry, Clin Transpl, 1
  3. Srinivas, 2008, Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result, Clin J Am Soc Nephrol, S101, 10.2215/CJN.03510807 · doi:10.2215/cjn.03510807
  4. Meier-Kriesche, 2004, Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era, Am J Transplant, 4, 378, 10.1111/j.1600-6143.2004.00332.x · DOI · Paper page
  5. Wieland, 2010, Biomarkers as a tool for management of immunosuppression in transplant patients, Ther Drug Monit, 32, 560, 10.1097/FTD.0b013e3181efb3d2 · DOI
  6. Bharat, 2007, Allopeptides and the alloimmune response, Cell Immunol, 248, 31, 10.1016/j.cellimm.2007.03.010 · DOI
  7. El-Sawy, 2002, Chemokines: directing leukocyte infiltration into allografts, Curr Opin Immunol, 14, 562, 10.1016/S0952-7915(02)00382-5 · DOI
  8. Barrett, 2003, New developments in allotransplant immunology, Hematology Am Soc Hematol Educ Program, 102, 350, 10.1182/asheducation-2003.1.350 · DOI
  9. Wucherpfennig, 2007, Polyspecificity of T cell and B cell receptor recognition, Semin Immunol, 19, 216, 10.1016/j.smim.2007.02.012 · DOI · Paper page
  10. Pasare, 2005, Toll-like receptors: linking innate and adaptive immunity, Adv Exp Med Biol, 560, 11, 10.1007/0-387-24180-9_2 · DOI · Paper page
  11. Kabelitz, 2007, Expression and function of Toll-like receptors in T lymphocytes, Curr Opin Immunol, 19, 39, 10.1016/j.coi.2006.11.007 · DOI · Paper page
  12. Raedler, 2010, Complement regulation of T-cell alloimmunity, Curr Opin Organ Transplant, 16, 54, 10.1097/MOT.0b013e3283425419 · DOI
  13. Suárez-Alvarez, 2009, Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention, Am J Transplant, 9, 251, 10.1111/j.1600-6143.2008.02526.x · doi:10.1111/j.1600-6143.2008.02526.x
  14. Yu, 2006, NK cells promote transplant tolerance by killing donor antigen-presenting cells, J Exp Med, 203, 1851, 10.1084/jem.20060603 · DOI · Paper page
  15. Clathworthy, 2011, Targeting B cells and antibody in transplantation, Am J Transplant, 11, 1359, 10.1111/j.1600-6143.2011.03554.x · DOI · Paper page
  16. Csencsits, 2003, Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction, Am J Transplant, 3, 107, 10.1034/j.1600-6143.2003.00036.x · DOI
  17. Häyry, 1994, Molecular pathology of acute and chronic rejection, Transplant Proc, 26, 3280
  18. Chatila, 1989, Mechanisms of T cell activation by the calcium ionophore ionomycin, J Immunol, 143, 1283, 10.4049/jimmunol.143.4.1283 · DOI · Paper page
  19. Zarling, 1976, A sensitive micromethod for generating and assaying allogeneically induced cytotoxic human lymphocytes, Transplantation, 21, 468, 10.1097/00007890-197606000-00005 · doi:10.1097/00007890-197606000-00005
  20. Trickett, 2003, T cell stimulation and expansion using anti-CD3/CD28 beads, J Immunol Methods, 275, 251, 10.1016/S0022-1759(03)00010-3 · DOI · Paper page
  21. Barten, 2001, Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro, J Immunol Methods, 253, 95, 10.1016/S0022-1759(01)00369-6 · DOI
  22. Leonardi, 1992, PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables, J Clin Pathol, 45, 416, 10.1136/jcp.45.5.416 · DOI · Paper page
  23. Palutke, 1989, A method for measuring lymphocyte proliferation in mixed lymphocyte cultures using a nuclear proliferation antigen, Ki-67, and flow cytometry, Am J Clin Pathol, 91, 417, 10.1093/ajcp/91.4.417 · doi:10.1093/ajcp/91.4.417
  24. Schlegel, 1997, The role of adhesion and costimulation molecules in graft-versus-host disease, Acta Haematol, 97, 105, 10.1159/000203666 · doi:10.1159/000203666
  25. Testi, 1989, T cell activation via Leu-23 (CD69), J Immunol, 143, 1123, 10.4049/jimmunol.143.4.1123 · DOI · Paper page
  26. Hintzen, 1995, Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation, J Immunol, 154, 2612, 10.4049/jimmunol.154.6.2612 · DOI · Paper page
  27. Schuurman, 1989, Expression of activation antigens on thymocytes in the ‘common thymocyte’ stage of differentiation, Thymus, 14, 43
  28. Miyawaki, 1992, Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood, J Immunol, 149, 3753, 10.4049/jimmunol.149.11.3753 · DOI · Paper page
  29. Li, 2009, Costimulatory pathways in transplantation: challenges and new developments, Immunol Rev, 229, 271, 10.1111/j.1600-065X.2009.00781.x · DOI · Paper page
  30. Ohnuma, 2008, Role of CD26/dipeptidyl peptidase IV in human T cell activation and function, Front Biosci, 13, 2299, 10.2741/2844 · DOI
  31. Ibegbu, 2009, Differential expression of CD26 on virus-specific CD8+ T cells during active, latent and resolved infection, Imunology, 126, 346, 10.1111/j.1365-2567.2008.02899.x · DOI
  32. Heemann, 1994, Adhesion molecules and transplantation, Ann Surg, 219, 4, 10.1097/00000658-199401000-00002 · DOI
  33. Tan, 2005, Chemokine receptors and transplantation, Cell Mol Immunol, 2, 343
  34. Holling, 2004, Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men, Hum Immunol, 65, 282, 10.1016/j.humimm.2004.01.005 · DOI · Paper page
  35. Boleslawski, 2011, CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long-term survivors after liver transplantation, Liver Transpl, 17, 299, 10.1002/lt.22232 · DOI
  36. Biselli, 1992, Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes, Scand J Immunol, 35, 439, 10.1111/j.1365-3083.1992.tb02879.x · doi:10.1111/j.1365-3083.1992.tb02879.x
  37. Barten, 2004, Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood, Transplantation, 77, 1154, 10.1097/01.TP.0000120391.42712.E8 · doi:10.1097/01.tp.0000120391.42712.e8
  38. Niwa, 2009, Stimulation index for PCNA mRNA in peripheral blood as immune function monitoring after renal transplantation, Transplantation, 87, 1411, 10.1097/TP.0b013e3181a277bb · DOI
  39. Böhler, 1998, The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation, Transplant Proc, 30, 2195, 10.1016/S0041-1345(98)00588-0 · doi:10.1016/s0041-1345(98)00588-0
  40. Augustine, 2007, Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin, J Clin Lab Anal, 21, 265, 10.1002/jcla.20182 · doi:10.1002/jcla.20182
  41. Wu, 1991, Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation, Transplant Proc., 23, 238
  42. Shipkova, 2001, The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, Transplant Proc, 33, 1080, 10.1016/S0041-1345(00)02424-6 · doi:10.1016/s0041-1345(00)02424-6
  43. Lyons, 1994, Determination of lymphocyte division by flow cytometry, J Immunol Methods, 71, 131, 10.1016/0022-1759(94)90236-4 · DOI · Paper page
  44. Babel, 2009, Lymphocyte markers and predicition of long-term renal allograft acceptance, Curr Opin Nephrol Hypertens, 18, 489, 10.1097/MNH.0b013e3283318f82 · DOI
  45. Böhler, 2007, Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans, Ther Drug Monit, 29, 77, 10.1097/FTD.0b013e318030a40b · DOI
  46. Dambrin, 2000, Pharmacodynamics of immunosuppressive drugs, Curr Opin Immunol, 12, 557, 10.1016/S0952-7915(00)00138-2 · doi:10.1016/s0952-7915(00)00138-2
  47. Kubbies, 1985, Cell cycle kinetics by BrdU-Hoechst flow cytometry: an alternative to the differential metaphase labeling, Cell Tissue Kinet, 18, 551
  48. Shaw, 1995, Analytic requirements for immunosuppressive drugs in clinical trials, Ther Drug Monit, 17, 577, 10.1097/00007691-199512000-00006 · doi:10.1097/00007691-199512000-00006
  49. Davis, 2011, Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry, J Immunol Methods, 363, 158, 10.1016/j.jim.2010.09.029 · DOI
  50. Fletcher, 1987, Use of whole blood methods in assessment of immune parameters in immunodeficiency states, Diagn Clin Immunol, 5, 69
  51. Rainen, 2002, Stabilization of mRNA expression in whole blood samples, Clin Chem, 48, 1883, 10.1093/clinchem/48.11.1883 · DOI · Paper page
  52. Wieland, 2011, Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study, Ther Drug Monit, 33, 341, 10.1097/FTD.0b013e3182188675 · doi:10.1097/ftd.0b013e3182188675
  53. Berry, 2006, Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses, Cytometry A, 69, 95, 10.1002/cyto.a.20200 · doi:10.1002/cyto.a.20200
  54. Wang, 2007, The unexpected effect of cyclosporin A on CD56+CD16− and CD56+CD16+ natural killer cell subpopulations, Blood, 110, 1530, 10.1182/blood-2006-10-048173 · DOI
  55. Barten, 2003, Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood, J Immunol Methods, 283, 99, 10.1016/j.jim.2003.08.015 · doi:10.1016/j.jim.2003.08.015
  56. Shipkova, 2009, Effect of immunosuppressants on CD26/dipetidyl peptidase IV expression on CD3 in vitro, Ther Drug Monit, 31, 660
  57. He, 2011, Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation, Am J Transplant, 11, 439, 10.1111/j.1600-6143.2010.03413.x · DOI
  58. Sindhi, 2003, Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications, J Immunol Methods, 272, 257, 10.1016/S0022-1759(02)00326-5 · doi:10.1016/s0022-1759(02)00326-5
  59. Van Rijen, 2003, Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules, Immunology, 109, 109, 10.1046/j.1365-2567.2003.01635.x · doi:10.1046/j.1365-2567.2003.01635.x
  60. Stalder, 2003, Quantification of immunosuppression by flow cytometry in stable renal transplant recipients, Ther Drug Monit, 25, 22, 10.1097/00007691-200302000-00003 · doi:10.1097/00007691-200302000-00003
  61. Prémaud, 2011, Inibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships, Pharmacol Res, 63, 432, 10.1016/j.phrs.2011.01.005 · doi:10.1016/j.phrs.2011.01.005
  62. Kamar, 2009, Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation, Clin J Am Soc Nephrol, 4, 936, 10.2215/CJN.04860908 · doi:10.2215/cjn.04860908
  63. Hutchinson, 2003, Laboratory assessment of immune function in renal transplant patients, Nephrol Dial Transplant, 18, 983, 10.1093/ndt/gfg190 · doi:10.1093/ndt/gfg190
  64. Böhler, 2008, Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients, Int Immunopharmacol, 8, 769, 10.1016/j.intimp.2008.01.023 · doi:10.1016/j.intimp.2008.01.023
  65. Weigel, 2001, Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients, J Heart Lung Transplant, 21, 1074, 10.1016/S1053-2498(02)00440-0 · DOI
  66. Canivet, 2008, T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus, Transpl Proc, 40, 3422, 10.1016/j.transproceed.2008.06.062 · doi:10.1016/j.transproceed.2008.06.062
  67. Barten, 2005, Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients, Transplant Proc, 37, 4532, 10.1016/j.transproceed.2005.10.091 · doi:10.1016/j.transproceed.2005.10.091
  68. Barten, 2007, Pharmacodynamics of T-cell function for monitoring immunosuppression, Cell Prolif, 40, 50, 10.1111/j.1365-2184.2007.00413.x · doi:10.1111/j.1365-2184.2007.00413.x
  69. Morteau, 2010, Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo, PLoS One, 12, e13294, 10.1371/journal.pone.0013294 · DOI
  70. Deng, 1998, T-cell and monocyte subsets, inflammatory molecules, rejection, and hemodynamics early after cardiac transplantation, Transplantation, 65, 1255, 10.1097/00007890-199805150-00018 · DOI
  71. Beik, 1998, Serial flow cytometric analysis of T-cell surface markers can be useful in differential diagnosis of renal allograft dysfunction, Clin Transplant, 12, 24, 10.1111/j.1399-0012.1998.tb01064.x · doi:10.1111/j.1399-0012.1998.tb01064.x
  72. Chang, 1996, Cytokines and cell surface markers in prediction of cardiac allograft rejection, Immunol Invest, 25, 13, 10.3109/08820139609059287 · doi:10.3109/08820139609059287
  73. Boleslawski, 2008, CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation, Clin Transplant, 22, 494, 10.1111/j.1399-0012.2008.00815.x · doi:10.1111/j.1399-0012.2008.00815.x
  74. Roberti, 2001, Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry—correlation with clinical outcome, Transplantation, 71, 1317, 10.1097/00007890-200105150-00024 · doi:10.1097/00007890-200105150-00024
  75. Sindhi, 2005, Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection, Am J Transplant, 5, 96, 10.1111/j.1600-6143.2004.00639.x · doi:10.1111/j.1600-6143.2004.00639.x
  76. Sindhi, 2005, Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28− T-suppressor cells, Hum Immunol, 66, 252, 10.1016/j.humimm.2004.05.017 · DOI
  77. Ashokkumar, 2010, Allospecific CD154+ B cells associate with intestine allograft rejection in children, Transplantation, 90, 1226, 10.1097/TP.0b013e3181f995ce · DOI
  78. Ashokkumar, 2009, Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation, Am J Transplant, 9, 179, 10.1111/j.1600-6143.2008.02459.x · DOI
  79. Millán, 2010, Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy, Clin Immunol, 137, 337, 10.1016/j.clim.2010.08.004 · DOI
  80. Latek, 2009, Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation, Transplantation, 87, 926, 10.1097/TP.0b013e31819b5a58 · DOI
  81. Newell, 2010, Identification of a B cell signature associated with renal transplant tolerance in humans, J Clin Invest, 120, 1836, 10.1172/JCI39933 · DOI · Paper page
  82. Sagoo, 2010, Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans, J Clin Invest, 120, 1848, 10.1172/JCI39922 · DOI · Paper page

Cited by

See all 210

Metadata

Authors
Shipkova, M., & Wieland, E.
Venue
Clinica Chimica Acta
Publisher
Elsevier BV
Published
2012-09
Volume
413
Issue
17-18
Pages
1338-1349
ISSN
0009-8981 (ISSN-L)
OpenAlex
W2007190645
Cited by
210
References
2
FWCI
5.04
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.